Showing 3761-3770 of 5092 results for "".
- Dr. Jennifer Schoch Wins NEA/PeDRA 2021 Childhood Eczema Challenge Granthttps://practicaldermatology.com/news/dr-jennifer-schoch-wins-neapedra-2021-childhood-eczema-challenge-grant/2460878/The National Eczema Association (NEA) and the
- Sofwave Medical Goes Public on the Tel Aviv Stock Exchangehttps://practicaldermatology.com/news/sofwave-medical-goes-public-on-the-tel-aviv-stock-exchange/2460824/Sofwave Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE) and raised $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters. The company has developed Synchronous Ul
- Galderma's Nemolizumab Performs Well in Phase 2b for ADhttps://practicaldermatology.com/news/galdermas-nemolizumab-performs-well-in-phase-2b-for-ad/2460739/Investigational nemolizumab led to rapid and sustained improvements in itch, sleep, and skin lesions in adult patients with uncontrolled moderate-to-severe AD in phase 2 studies published in Journal of the European Academy of Dermatology and Venereology (JEADV) and reported by
- Dr. Adam Friedman Named Chair of Dermatology at George Washington Universityhttps://practicaldermatology.com/news/dr-adam-friedman-named-chair-of-dermatology-at-george-washington-university/2460718/Adam Friedman, MD has been
- FDA Grants Priority Review of NDA for Incyte’s Ruxolitinib Cream for ADhttps://practicaldermatology.com/news/fda-grants-priority-review-of-nda-for-incytes-ruxolitinib-cream-for-ad/2460702/The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of Incyte’s ruxolitinib cream for atopic dermatitis (AD) for priority review. The Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2021. Ruxolitinib cream is
- FDA Approves Galderma's Restylane Defyne for Chin Augmentationhttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-defyne-for-chin-augmentation/2460676/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 201
- Study: Aerolase Neo Elite Laser Is as Effective as the Gold Standard Laser for Treating Psoriasishttps://practicaldermatology.com/news/study-aerolase-neo-elite-laser-is-as-effective-as-the-gold-standard-laser-for-treating-psoriasis/2460674/The efficacy and tolerance of the 650-microsecond 1064-nm Nd:YAG laser (Aerolase NeoElite) is equivalent to the excimer laser for the treatment of mild to moderate psoriasis vulgaris of the arms and legs, according to a new study in the Journal of Drugs in Dermatology.
- MyHealthTeams' "Gaining Control with Psoriasis" Challenge Empowers Psoriasis Patients to Change Things Uphttps://practicaldermatology.com/news/myhealthteams-gaining-control-with-psoriasis-challenge-empowers-psoriasis-patients-to-change-things-up/2460663/
- Dermatologists React to Reports of Adverse Events in Filler Patients Who Got COVID-19 Vaccineshttps://practicaldermatology.com/news/report-covid-19-vaccines-and-dermatology/2460648/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Six Investigators to Receive NEA Grants for Eczema Researchhttps://practicaldermatology.com/news/six-investigators-to-receive-nea-grants-for-eczema-research/2460638/The